The most common grade 3–4 adverse events related to dalpiciclib were hematologic toxicities, primarily neutropenia and leukopenia, which were effectively managed through dose modifications and granulocyte colony-stimulating factor support. The gene discussed is CSF3; the disease is neutropenia.